The world's biggest makers of insulin are likely to make more money, not less, even after slashing prices by as much as 75% due to US government pressure.
That's because Novo Nordisk announced price cuts to their insulin products on Tuesday, less than two weeks after rival Eli Lilly & Co. announced its own price cuts. However, both companies could avoid paying out multimillion-dollar rebates to the government's Medicaid health-care program.
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
NOT FOR REPRINT
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
